is tirzepatide insulin or non insulin for diabetes: on track to SURPASS current therapy Frontiers | Tirzepatide against obesity

Semma (Semaglutide) Oral was effective in patients with type 2 diabetes and moderate renal impairment, potentially providing a new treatment option for this population."

We're all kind of stressed

Between July 2023 - when Intuitive first mentioned weight loss drugs - and October 2023, medical device companies that were deemed GLP-1 losers sold off aggressively (e.g., diabetes medical devices, sleep apnea devices, bariatric surgery), while the GLP-1 companies themselves (Eli Lilly and Novo Nordisk) increased in value much more than the broader market

Stapled peptides for intracellular drug targets

If youre currently taking a compounded GLP-1, its a good time to talk with your healthcare provider about next steps